轉譯醫學生物標的對業界的影響

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

In This Issue...

Failure rates for the development of new drugs will continue to rise if basic research findings cannot be quickly turned into valuable medicines. The result of increasing drug failures will be a pharmaceutical industry that is unsustainable, an industry that will not be able to refresh lean drug development pipelines merely by pushing more preclinical projects into development. As a result, translational medicine is one of the fastest growing areas of drug discovery and development today. Biomarkers are at the heart of this effort. This report looks at the modernization of the drug development process through widespread adoption of translational studies using biomarkers. We discuss different types of biomarkers, including the potential use of new imaging technologies, and assess whether these changes are sufficient to reverse the industry's productivity decline. We review two case studies on drugs that could have benefited from having clinic-ready biomarkers and examine what lessons can be learned. Lastly, some companies are engaged in developing biomarkers in combination with drugs. We discuss some of these companies, their products, and the role of the FDA in promoting such co-development activities.

Table of Contents

• The Dawn of Translational Medicine
• Recent FDA Initiatives
• Uses of Biomarkers
• The FDA's Support and Direct Involvement in Improving the Development of Medical Products
  • Research Biomarkers
    • Cancer Research
    • Alzheimer's Disease Research
  • Toxicity Biomarkers
  • Pharmacogenetic Biomarkers
• The Value of Clinic-Ready Biomarkers
  • Lessons to Be Learned from the COX-2 Inhibitor Rofecoxib (Vioxx)
  • Lessons to Be Learned from Gefitinib (AstraZeneca's Iressa)
• Unique Challenges of Genomic Data
  • The FDA's Position on Pharmacogenomic Data
  • Genomic Biomarkers in the Clinic
• High Hopes for New Imaging Techniques
• Theranostics/Companion Diagnostics
  • Roche Diagnostics and Lilly Cancer Drugs
  • Clinical Data's Depression Drug Test
  • Bristol-Myers Squibb's Commitment
• Potential Impact of Biomarker Use
• Addendum: Critical Path Opportunities List of 76 Priority Projects-March 2006

相關商品

生物材料相關市場調查報告書

歐洲的整形外科生醫材料市場:2012年
European Markets for Orthopedic Biomaterials 2012
價格 : US $ 6995
出版日期 : 2011年12月

亞洲的整形外科生醫材料市場:2012年
Asia Pacific Markets for Orthopedic Biomaterials
價格 : US $ 5995
出版日期 : 2011年12月

美國的整形外科生醫材料市場:2012年
US Markets for Orthopedic Biomaterials 2012
價格 : US $ 6995
出版日期 : 2011年11月

Decision Resources, Inc.發行的生物科技相關市場調查報告書

以生物標記來預測自體免疫疾病生物療法的反應

Special Report: Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases

價格 : US $ 9200

出版日期 : 2011年06月

成為下一波一鳴驚人藥物的新一代治療用抗體的尋求

Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs

價格 : US $ 4600

出版日期 : 2011年06月

探索讓個人化醫療進化的資訊技術工具

Exploiting Information Technology Tools to Advance Personalized Medicine

價格 : US $ 4600

出版日期 : 2011年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!